Novo Nordisk's 15 Billion Kroner Buyback and Wegovy Pill Triumph Face a $25 Million Ransomware Threat
17.06.2026 - 10:52:58 | boerse-global.de
The management team at Novo Nordisk has been sending a clear message of confidence to shareholders by aggressively repurchasing its own stock. Since February, the Danish pharmaceutical giant has authorized a buyback program worth up to 15 billion Danish kroner, with more than a third already deployed. By mid-June, the company had spent roughly 5.27 billion kroner to acquire its own shares, building a treasury stake equivalent to 0.8% of total equity. The move props up the share price at a time when the company is juggling a remarkable product success with a serious cybersecurity crisis.
That crisis erupted when the hacker group FulcrumSec breached Novo Nordisk's systems and made off with a staggering 1.3 terabytes of internal data. The haul includes source codes for medications, clinical trial results, and files from the secretive AI project "Dragonfly." In addition, records of 163,000 employees were stolen, along with pseudonymised profiles of 11,500 study patients — names were shielded, but age and health information are exposed. The hackers are demanding $25 million in ransom. Novo Nordisk has refused to pay, prompting FulcrumSec to threaten a sale of 700,000 individual files to private buyers. If the data leak is linked to negligence, the company could face European GDPR fines of up to 4% of annual revenue.
Yet in the operating business, momentum is building from an unexpected direction. The oral version of Wegovy, launched in the United States just five months ago, has already surpassed three million prescriptions. Weekly, physicians now write 116,000 scripts for the injection version, giving Novo Nordisk a dominant hold on more than half of the global weight?loss market. The British Medicines and Healthcare products Regulatory Agency officially approved the Wegovy pill on Tuesday, opening a second major market. CEO Mike Doustdar has also announced that a Chinese approval for the oral tablet is imminent, a direct challenge to rival Eli Lilly in the world’s second?largest pharmaceutical market. China still offers Novo Nordisk data exclusivity for the active ingredient semaglutide until early 2027.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
This volume explosion is badly needed to offset price erosion. Government reimbursement agreements in the United States are squeezing margins, and in some international markets semaglutide is losing patent protection. Novo Nordisk’s adjusted first?quarter revenue slipped 4%, yet management raised its full?year guidance, betting that rapid script growth will outweigh the pricing headwinds. To meet demand, the company is pouring $6.5 billion into U.S. production facilities, which now run around the clock. The FDA recently declared that supply shortages for Wegovy and Ozempic are over.
Against this mix of operational wins and security risks, the stock has struggled to gain traction. Novo Nordisk shares recently traded at around €38, recovering from a 12?month low near €30 but still down roughly 41% over the past year. Technical indicators are mixed: one measure shows the stock has reclaimed its 50?day moving average of €36.75, while another puts that average at €41.34 and notes a neutral momentum reading from the relative strength index. The gap between the current price and the year’s high exceeds 42%.
The international rollout of the Wegovy pill will begin in the second half of 2026, starting with the United Arab Emirates. If the global expansion succeeds, it will further cushion the blow from U.S. price pressure. But investors now face a more immediate question: will the hackers follow through on their threat to publish internal documents? Should that happen, the trust of patients and regulators alike could be severely damaged, adding a fresh layer of uncertainty to an otherwise promising turnaround story.
Ad
Novo Nordisk Stock: New Analysis - 17 June
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
